The migration of hematopoietic stem cells (HSCs) is evident in several circumstances. During development, HSCs seed new sites of hematopoiesis, and under physiological conditions in adult life, HSCs continuously move between the bone marrow and the bloodstream. Also, a massive efflux of HSCs, a process called mobilization, occurs following treatment with cytotoxic drugs or cytokines such as granulocyte colony-stimulating factor (G-CSF), whereas following intravenous injection into transplant recipients, HSCs migrate to and engraft in the bone marrow. Although the mobilization and transplantation of HSCs is widely used in modern clinical medicine, the precise mechanisms by which HSCs exit their niche or reengage their niche after transplantation are still being unraveled. Katayama et al. (2006) now report that the sympathetic nervous system is a key and previously unrecognized participant in HSC mobilization.
As a result of more than four decades of studies using mostly rodent models and an equally long clinical tradition of bone-marrow transplantation regimens, HSCs are the best characterized population of stem cells. However, the field has been held back by an imprecise understanding of the microenvironment, or niche, in which the HSCs reside. This, for obvious reasons, has hampered detailed investigation of the mobilization and engraftment process. Studies of the HSC microenvironment have been limited by the fact that the most liquid of tissues, bone marrow, is encased by the most solid. By labeling stem cells and reinfusing them, it has been shown that HSCs reside in close proximity to the endosteal bone surface, and the assumption has been made that maturing cells become redistributed toward the central marrow region. Recently, two genetic studies identified osteoblasts as crucial cellular components of the HSC microenvinervous Activity in a stem cell niche Jonas Larsson 1,2,3 and David Scadden 1,2, * ronment and thus have defined a niche for HSCs (Zhang et al., 2003; Calvi et al., 2003) . Subsequently, advanced imaging studies have demonstrated that the HSCs reside in close proximity to the bone-lining osteoblasts (Arai et al., 2004) as well as blood vessels, which may constitute an alternative niche (Kiel et al., 2005) . New insights into the mechanisms by which HSCs egress from (or are retained by) the niche are likely to emerge from these anatomical descriptions.
The cytokine G-CSF is the most widely used mobilizing agent for HSCs in experimental as well as clinical settings. It has been postulated that G-CSF triggers the release of specific proteases, leading to the degradation of adhesion molecules and chemokines. In particular, CXCL12 or stromal-derived factor 1 (SDF-1) and its receptor CXCR4 have been implicated as a key ligand-receptor pair responsible for retention of HSCs in the bone marrow (Papayannopoulou, 2004) . However, mice deficient in several of these proteases exhibit normal G-CSF-induced mobilization of HSCs, indicating that other, as yet unknown, mechanisms must be involved. Given that the ability to mobilize stem cells varies between patients, these processes beg further investigation. The work of Katayama et al. (2006) takes a step into this void, providing a mechanism for G-CSF-induced mobilization of HSCs and suggesting that the sympathetic nervous system may regulate stem cell trafficking. Remarkably, the study started out from a completely different angle before arriving at these unanticipated and intriguing conclusions.
Several years ago, Paul Frenette and his group observed that the sulfated fucose polymer fucoidan causes rapid mobilization of HSCs (Frenette and Weiss, 2000) . In order to assess whether a very similar molecule synthesized by mammalian cells, a sulfated galactolipid called sulfatide, might contribute to the endogenous mobilization process, Frenette and colleagues studied mice deficient in the UDP-galactose:ceramide galactosyltransferase (Cgt). Cgt is essential for the synthesis of sulfatide by mediating the addition of UDP-galactose to ceramide. The authors found that mice lacking Cgt exhibited severely impaired mobilization in response to G-CSF. Unexpectedly, they found that the mobilization defect in mice lacking Cgt could not be linked to the lack of sulfatide and that another indirect mechanism had to be involved. The products of Cgt contribute to the myelin sheath surrounding nerves, and Cgt-deficient mice exhibit defective nerve transmission. Frenette and colleagues speculated that impaired transmission of nervous-system signals could play a role in the mobilization defect. In fact, this was not an entirely farfetched hypothesis for several reasons. First, a role for the sympathetic nervous system in regulating bone formation is well established, and it has been elegantly demonstrated that adrenergic signals directly regulate osteoblast function (Takeda et al., 2002) . Secfigure 1. signals from the sympathetic nervous system modulate localization of Hematopoietic stem cells to the endosteal niche in Bone G-CSF activation of peripheral noradrenergic neurons (thick green arrow) together with an unknown mechanism (green dashed arrow) induces mobilization of hematopoietic stem cells (HSCs) through suppression of osteoblasts and a decrease in CXCL12. HSC mobilization by G-CSF was studied in mouse models with defects in nerve conduction (Katayama et al., 2006) . These models included mice deficient in the UDP-galactose:ceramide galactosyltransferase (Cgt −/− ); mice deficient in dopamine β-hydroxylase (Dbh −/− ); mice injected postnatally with 6-hydroxydopamine (6OHDA), which disrupts catecholaminergic neurons; and mice treated with β blockers (β antagonists). Additionally, a β2-adrenergic agonist rescues the mobilization defects in mice deficient in dopamine β-hydroxylase and augments G-CSF-induced mobilization in control mice. These studies demonstrate that noradrenergic signals from the sympathetic nervous system are critical mediators of G-CSF-induced mobilization.
ond, HSCs reside in close proximity to osteoblasts at the endosteal surface. Third, the authors have demonstrated that G-CSF treatment causes suppression of osteoblasts, leading to a decrease in the chemokine CXCL12. Normally, CXCL12 is highly expressed in bone tissues and is believed to be critical for the attraction of HSCs to the niche. Similar findings were recently reported in an independent study by Semerad and colleagues (Semerad et al., 2005) . In order to back up their theory that the nervous system has a role in mediating HSC mobilization, Katayama et al. (2006) examined a battery of genetic and pharmacological mouse models with impaired nerve conduction in addition to the mice lacking Cgt. These included mice lacking dopamine β-hydroxylase (Dbh −/− ), which have deficient synthesis of norepinephrine; mice subjected to pharmacological disruption of catecholaminergic neurons through postnatal injections of 6-hydroxydopamine (6OHDA); and mice treated with β blockers (Figure 1) . Each of the models resulted in decreased HSC mobilization in response to G-CSF. Osteoblast suppression was not observed in these models, and CXCL12 levels remained intact. This strongly suggests that noradrenergic signals from the sympathetic nervous system are critical mediators of G-CSF-induced mobilization (Figure 1 ). Involvement of noradrenergic activity was further supported by the observation that norepinephrine levels decreased in the bone following G-CSF stimulation, a sign that norepinephrine was depleted through its release. Additionally, a β2-adrenergic agonist could rescue the mobilization defects in mice lacking dopamine β-hydroxylase and caused an overall augmentation of G-CSF-induced mobilization in control mice (Figure 1) . Importantly, however, adrenergic stimulation in the absence of G-CSF treatment could not induce mobilization, suggesting that the sympathetic nervous system is not the sole downstream target of G-CSF and that another, as yet unidentified, parallel mechanism of mobilization must exist.
The findings by Katayama et al. (2006) suggest that the pharmacological manipulation of the sympathetic nervous system may be a means of therapeutically targeting the stem cells in their niche for the purpose of either mobilization or, conversely, attracting stem cells to the niche following transplantation. Because adrenergic agonists and antagonists exist and have been used in the clinic without major deleterious effects, such trials may become a reality in the near future. However, the implication of greatest importance may be in a more generic biological context: Given that hematopoiesis occurs at multiple locations in the bones throughout the body, it has not been clear how hematopoietic homeostasis is maintained. The continuous migration of HSCs between bone marrow and the bloodstream that occurs under normal physiological conditions (Wright et al., 2001) could serve to maintain hematopoietic homeostasis. HSC niches that are left empty following stem cell death or differentiation can be reseeded by circulating stem cells released from other niches, but such trafficking must occur under a certain level of systemic control. Given the new findings, it is tempting to speculate that the nervous system could play an important role in regulating hematopoietic homeostasis by influencing the migration and localization of stem cells among different bone-marrow niches.
From the groundbreaking nature of the Katayama et al. study, there follows naturally a number of loose ends and questions that require further investigation. Perhaps the most important task will be to define how G-CSF interacts with its neuronal targets. The authors demonstrate convincingly that neuronal activation by G-CSF occurs in the peripheral rather than the central nervous system, but, as they point out, it is not clear whether G-CSF acts directly on neurons or through adjacent glial cells or other indirect targets. Furthermore, it will be interesting to determine whether the mechanisms of neuronal regulation also apply to HSCs that have a perivascular localization (Kiel et al., 2005) in addition to the osteoblastic niche that was examined here. Specialized vascular domains with high CXCL12 content have been identified in the bone-marrow vasculature, which may serve as ports of entry for circulating stem cells (Sipkins et al., 2005) . It is an attractive idea that these particular domains may be subject to regulation by the sympathetic nervous system. Finally, it will be important to identify the missing variables that act downstream of G-CSF, which, together with sympathetic signals, modulate the mobilization process.
Nevertheless, the stage is now set for creative science for both experimental and clinical investigators in the field. To start with, we will all have to reset our thinking about the fundamental interactions in the bone-marrow niche that affect the mobility of stem cells. Bone marrow, bone, and the nervous system now appear to integrate signals to regulate HSCs. If hematopoiesis is any guide, niches may be nodal points where multiple, previously disconnected systems collide.
